The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation

British Journal of Haematology

Volumn 128, Issue 2, 2005, Pages 224-233

  Cesaro, Simone ^a   Murrone, Antonio ^a   Mengoli, Carlo ^a   Pillon, Marta ^a   Biasolo, Maria A ^a   Calore, Elisabetta ^a   Tridello, Gloria ^a   Varotto, Stefania ^a   Alaggio, Rita ^a   Zanesco, Luigi ^a   Palù, Giorgio ^a   Messina, Chiara ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Epstein Barr virus; Haematopoietic stem cell transplantation; Paediatric malignancies; Post transplant lymphoproliferative diseases; Real time polymerase chain reaction

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISONE; STEROID; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; DISEASE EXACERBATION; DONOR; EPSTEIN BARR VIRUS; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL; VIRUS GENOME; VIRUS LOAD; VIRUS REACTIVATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSION; INFANT; LYMPHOPROLIFERATIVE DISORDERS; MALE; POSTOPERATIVE PERIOD; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; VIRUS ACTIVATION;

EID: 19944433867     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05287.x     Document Type: Article

References (35)

1. Bearman, S.I., Appelbaum, F.R., Back, A., Petersen, F.B., Buckner, C.D., Sullivan, K.M., Schoch, H.G., Fisher, L.D. & Thomas, E.D. (1989) Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. Journal of Clinical Oncology, 7, 1288-1294.
2. Bhatia, S., Ramsay, N.K., Steinbuch, M., Dusenbery, K.E., Shapiro, R.S., Weisdorf, D.J., Robison, L.L., Miller, J.S. & Neglia, J.P. (1996) Malignant neoplasms following bone marrow transplantation. Blood, 87, 3633-3639.
3. Biasolo, M.A., Calistri, A., Cesaro, S., Gentile, G., Mengoli, C. & Palù, G. (2003) Case report: kinetics of Epstein-Barr virus load in a bone marrow transplant patient with no sign of lymphoproliferative disease. Journal of Medical Virology, 69, 220-224.
4. Cesaro, S., Buoro, S., D'Amore, E., Locatelli, F., Comolli, P., Gazzola, M., Destro, R., Palù, G. & Zanesco, L. (2002) EBV lymphoma in paediatric bone marrow transplant patients. Bone Marrow Transplantation, 30(suppl. 1), 55.
5. Davis, T.A., Czerwinski, D.K. & Levy, R. (1999) Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clinical Cancer Research, 5, 611-615.
6. Deeg, J.H. & Sociè, G. (1998) Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood, 91, 1833-1844.
7. van Esser, J.W., van der Holt, B., Meijer, E., Niesters, H.G., Trenschel, R., Thijsen, S.F., van Loon, A.M., Frassoni, F., Bacigalupo, A., Schaefer, U.W., Osterhaus, A.D., Gratama, J.W., Lowenberg, B., Verdonck, L.F. & Cornelissen, J.J. (2001) Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood, 98, 972-978.
8. Farag, S.S. (2004) Chronic graft versus host disease: where do we go from here? Bone Marrow Transplantation, 33, 569-577.
9. Faye, A., Quartier, P., Reguerre, Y., Lutz, P., Garret, A.S., Dehee, A., Rohrlich, P., Peuchmaur, M., Matthieu-Boue, A., Fischer, A. & Vilmer, E. (2001) Chimeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation. British Journal of Haematology, 115, 112-118.
10. Gartner, B.C., Schafer, H., Marggraff, K., Eisele, G., Schafer, M., Dilloo, D., Roemer, K., Laws, H.J., Sester, M., Sester, U., Einsele, H. & Mueller-Lantzsch, N. (2002) Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. Journal of Clinical Microbiology, 40, 351-358.
11. Goodman, J.L., Winston, D.J., Greenfield, R.A., Chandrasekar, P.H., Fox, B., Kaizer, H., Shadduck, R.K., Shea, T.C., Stiff, P., Friedman, D.J., Powderly, W.G., Silber, J.L., Horowitz, H., Lichtin, A., Wolff, S.N., Mangan, K.F., Silver, S.M., Weisdorf, D., Winston, G.H., Gilbert, G. & Buell, D. (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. The New England Journal of Medicine, 326, 845-851.
12. Gottschalk, S., Ng, C.Y., Perez, M., Smith, C.A., Sample, C., Brenner, M.K., Heslop, H.E. & Rooney, C.M. (2001) An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood, 97, 835-843.
13. Gross, T.G., Steinbuch, M., DeFor, T., Shapiro, R.S., McGlave, P., Ramsay, N.K., Wagner, J.E. & Filipovich, A.H. (1999) B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplantation, 23, 251-258.
14. Gruhn, B., Meerbach, A., Hafer, R., Zell, R., Wutzler, P. & Zintl, F. (2003) Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 31, 1023-1025.
15. Gustafsson, A., Levitsky, V., Zou, J.Z., Frisan, T., Dalianis, T., Ljungman, P., Ringden, O., Winiarski, J., Ernberg, I. & Masucci, M.G. (2000) Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytoxic T cells. Blood, 95, 807-814.
16. Hoshino, Y., Kimura, H., Tanaka, N., Tsuge, I., Kudo, K., Horibe, K., Kato, K., Matsuyama, T., Kikuta, A., Kojima, S. & Morishima, T. (2001) Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative poymerase chain reaction after allogeneic stem cell transplantation. British Journal of Haematology, 115, 105-111.
17. Kernan, N.A., Bartsch, G., Ash, R.C., Beatty, P.G., Champlin, R., Filipovich, A., Gajewski, J., Hansen, J.A., Henslee-Downey, J., McCullough, J., McGlave, P., Perkins, H.A., Phillips, G.L., Sanders, J., Stroncek, D., Thomas, E.D. & Blume, K.G. (1993) Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program. The New England of Journal Medicine, 328, 593-602.
18. Knowles, D.M., Cesarman, E., Chadburn, A., Frizzera, G., Chen, J., Rose, E.A. & Michler, R.E. (1995) Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood, 85, 552-565.
19. Kuehnle, I., Huls, M.H., Liu, Z., Semmelmann, M., Krance, R.A., Brenner, M.K., Rooney, C.M. & Heslop, H.E. (2000) CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hematopoietic stem cell transplantation. Blood, 95, 1502-1505.
20. Laichalk, L.L., Hochberg, D., Babcock, G.J., Freeman, R.B. & Thorley-Lawson, D.A. (2002) The dispersal of mucosal memory B cells: evidence from persistent EBV infection. Immunity, 16, 745-754.
21. Loren, A.W., Porter, D.L., Stadtmauer, E.A. & Tsai, D.E. (2003) Posttransplant lymphoproliferative disorder: a review. Bone Marrow Transplantation, 31, 145-155.
22. Lucas, K.G., Burton, R.L., Zimmerman, S.E., Wang, J., Cornetta, K.G., Robertson, K.A., Lee, C.H. & Emanuel, D.J. (1998) Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood, 91, 3654-3661.
23. McDonald, G.B., Hinds, M.S., Fisher, L.D., Schoch, H.G., Wolford, J.L., Banaji, M., Hardin, B.J., Shulman, H.M. & Clift, R.A. (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Annals of Internal Medicine, 118, 255-267.
24. McGuirk, J.P., Seropian, S., Howe, G., Smith, B., Stoddart, L. & Cooper, D.L. (1999) Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplantation, 24, 1253-1258.
25. Miyashita, E.M., Yang, B., Lam, K.M., Crawford, D.H. & Thorley-Lawson, D.A. (1995) A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell, 80, 593-601.
26. Papadopoulos, E.B., Ladanyi, M., Emanuel, D., Mackinnon, S., Boulad, F., Carabasi, M.H., Castro-Malaspina, H., Childs, B.H., Gillio, A.P., Small, T.N., Young, J.W., Kernan, N.A. & O'Reilly, R.J. (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. The New England Journal of Medicine, 330, 1185-1191.
27. Rooney, C.M., Loftin, S.K., Holladay, M.S., Brenner, M.K., Krance, R.A. & Heslop, H.E. (1995) Early identification of Epstein-Barr virus associated post-transplant lymphoproliferative disease. British Journal of Haematology, 89, 98-103.
28. Rooney, C.M., Smith, C.A., Ng, C.Y., Loftin, S.K., Sixbey, J.W., Gan, Y., Srivastava, D.K., Bowman, L.C., Krance, R.A., Brenner, M.K. & Heslop, H.E. (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 92, 1549-1555.
29. Sirvent-von Bueltzingsloewen, A., Morand, P., Buisson, M., Souillet, G., Chambost, H., Bosson, J.L. & Bordigoni, P. (2002) A prospective study of Epstein-Barr virus load in 85 hematopoietic stem cell transplants. Bone Marrow Transplantation, 29, 21-28.
30. Socie, G., Curtis, R.E., Deeg, H.J., Sobocinski, K.A., Filipovich, A.H., Travis, L.B., Sullivan, K.M., Rowlings, P.A., Kingma, D.W., Banks, P.M., Travis, W.O., Witherspoon, K.P., Sanders, J., Jaffe, E.S. & Horowitz, M.M. (2000) New malignant disease after allogeneic marrow transplantation for childhood acute leukemia. Journal of Clinical Oncology, 18, 348-357.
31. Sullivan, K.M. (1986) Acute and chronic graft-versus-host disease in man. International Journal of Cell Cloning, 4, 42-93.
32. Tsai, D.E., Hardy, C.L., Tomaszewski, J.E., Kotloff, R.M., Oltoff, K.M., Somer, B.C., Schuster, S.J., Porter, D.L., Montone, K.T. & Stadtmauer, E.A. (2001) Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 patients. Transplantation, 71, 1076-1088.
33. Verschuuren, E.A., Stevens, S., Pronk, I., Van Der bij, W., Harmsen, M.C., The, T.H., Meijer, C.J., Van Den Brule, A.J. & Middeldorp, J.M. (2001) Frequent monitoring of Epstein-Barr virus DNA load in unfractioned whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood, 97, 1165-1171.
34. Wagner, H.J., Rooney, C.M. & Henslop, H.E. (2002) Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 8, 1-8.
35. Wagner, H.J., Cheng, Y.C., Huls, M.H., Gee, A.P., Kuehnle, I., Krance, R.A., Brenner, M.K., Rooney, C.M. & Heslop, H.E. (2004) Prompt versus pre-emptive intervention for EBV-lymphoproliferative disease. Blood, 103, 3979-3981. Epub 2004 Jan 29.